Niacin: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Vitamin B3 *Dosage Forms: *Routes of Administration: oral *Common Trade Names: ==Adult Dosing== *Recommended daily allowance: 16mg/day (men), 14mg/...") |
No edit summary |
||
| Line 2: | Line 2: | ||
*Type: Vitamin B3 | *Type: Vitamin B3 | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: PO | ||
*Common Trade Names: | *Common Trade Names: Niaspan (extended release) | ||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 07:47, 1 September 2017
Administration
- Type: Vitamin B3
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: Niaspan (extended release)
Adult Dosing
- Recommended daily allowance: 16mg/day (men), 14mg/day (women)
- CAD, HLD: 250-6000mg PO daily in 2-3 divided doses
- Pellagra: 150-500mg PO daily in divided doses
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing: contraindicated in active liver disease/hepatic impairment or unexplained LFT abnormalities
Contraindications
- Allergy to class/drug
- Active liver disease or unexplained LFT abnormalities
- Peptic ulcer disease
- Arterial bleeding
Adverse Reactions
Serious
- Hepatotoxicity
- Rhabdomyolysis
Common
- Flushing (88%)
- Nausea/vomiting
Pharmacology
- Half-life: 20-45m
- Metabolism: Hepatic
- Excretion: Mostly renal